Holen Sie sich die Stockscreener-App
5.285
5.07%
0.255
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.03
Offen:
$5.1
24-Stunden-Volumen:
5.44M
Relative Volume:
0.63
Marktkapitalisierung:
$899.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.94M
KGV:
-18.42
EPS:
-0.2869
Netto-Cashflow:
$-30.62M
1W Leistung:
-4.43%
1M Leistung:
+47.21%
6M Leistung:
+185.68%
1J Leistung:
+355.60%
1-Tages-Spanne:
$5.10
$5.60
1-Wochen-Bereich:
$4.93
$6.14
52-Wochen-Spanne:
$0.9516
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
5.285 | 856.52M | 0 | -25.94M | -30.62M | -0.2869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.17 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.65 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.99 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.40 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.66 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.3% HigherWhat's Next? - MarketBeat
SELLAS enrolls first patient in Phase 2 AML trial of SLS009 - Investing.com India
SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial - Asianet Newsable
According to the latest merger agreement terms, Signature Bank shareholders will receive an equity allocation at a ratio of 2.63 shares of Esquire Financial Holdings Inc. for each share of Signature stock. - Bitget
Major Bank Ratings | Evercore ISI: Raises Ryanair target price to $80, rating upgraded to "Outperform" - Bitget
Sellas announces enrollment of first patient in Phase 2 SLS009 trial - TipRanks
SELLAS Life Sciences Group Inc. announced that the first patient has been enrolled in the clinical trial of its innovative drug SLS009 for first-line treatment of newly diagnosed acute myeloid leukemia (AML). - Bitget
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - The Manila Times
Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 - marketscreener.com
SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
SELLAS Strengthens Capital Base Through Warrant Exercises - TipRanks
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds - Investing.com UK
Sellas Life Sciences reports $42.6 million in warrant exercise proceeds By Investing.com - Investing.com Australia
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.2%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Aug Catalysts: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s Changed - Yahoo Finance
SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month HighStill a Buy? - MarketBeat
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout - Asianet Newsable
Trade Recap: Can SELLAS Life Sciences Group Inc beat the S P 5002026 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout - Stocktwits
Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial Updates - Yahoo Finance
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
Assessing SELLAS Life Sciences Group (SLS) Valuation After New Phase 3 REGAL Trial Progress News - simplywall.st
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst - Seeking Alpha
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SELLAS Life Sciences (SLS) Is Up 21.8% After REGAL Trial Clears Key Continuation ReviewWhat's Changed - simplywall.st
Wall Street Recap: Can SELLAS Life Sciences Group Inc beat the S P 500July 2025 Sentiment & Safe Entry Trade Signal Reports - baoquankhu1.vn
What's Going With SELLAS Life Sciences Stock On Wednesday? - Bitget
Bull Run: Will SELLAS Life Sciences Group Inc benefit from green energy policiesWeekly Market Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
SLS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SLS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
SLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
SLS Technical Analysis & Stock Price Forecast - Intellectia AI
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Asianet Newsable
SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - MarketBeat
Stock Surge: Solstice Minerals Breakthrough at Nanadie Adventure - timothysykes.com
Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play - Bez Kabli
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.8%Here's Why - MarketBeat
Solstice Minerals Shares Surge 56% on Successful Drilling Results - StocksToTrade
Anson group discloses 4.9% SELLAS Life Sciences (SLS) stake via 13G/A - Stock Titan
Profit Review: What is the target price for Green Dot Corporation stockJuly 2025 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):